Michael B. Atkins, MD
Adjuvant treatment for patients with high-risk melanoma has seen little progress until recently. This is in large part due to the lack of consensus in the community on what treatments to use, when to use them, and in which patients to implement them, explains Michael B. Atkins, MD.
on Melanoma, Atkins, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discussed hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.
OncLive®: Can you discuss your talk on adjuvant therapy for melanoma?
: Over the past 20 years, the adjuvant treatments that have been used for patients with high-risk melanoma were high-dose interferon, then pegylated interferon, and then high-dose ipilimumab. We constantly had arguments about whether these treatments should be used or not and in which patients. In truth, none of the treatments were effective enough or tolerable enough to justify their widespread use, particularly in the recent era where there are more effective systemic treatments for stage IV disease. We have been waiting for the data to come out on the treatments that we have been using in the stage IV setting [as adjuvant therapy].
... to read the full story